首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1738674

2026-2032 年 COVID-19 疫苗市场（按技术、应用和地区）

Covid-19 Vaccine Market By Technology (mRNA Technology, Viral Vector Technology), Application (Primary Vaccination, Booster Doses), & Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

COVID-19疫苗市场评估-2026-2032

社会对疫苗益处的认识不断提高，导致对新冠疫苗接种的需求增加。随着各国政府和组织加大对疫苗接种的资金投入和支持，预计2024年市场规模将超过76.4亿美元，到2032年将达到约126.4亿美元。

此外，疫苗研发和配送方法的创新提高了生产效率和分销管道，也刺激了新冠疫苗的推广。製药公司、政府和非政府组织之间的伙伴关係正在加速疫苗研发和分销工作，推动市场在2026年至2032年期间的复合年增长率达到7.16%。

COVID-19 疫苗市场：定义/概述

COVID-19 疫苗是生物製药，旨在帮助您获得对导致 COVID-19 的 SARS-CoV-2 病毒的免疫力。这些疫苗的工作原理是将病毒的无害成分（例如刺突蛋白或 mRNA）引入体内，以便您的免疫系统在将来接触病毒时识别并做出反应，从而帮助预防重症和感染。

新冠疫苗的应用对控制疫情至关重要。疫苗宣传活动旨在实现人群广泛免疫，并显着降低了与病毒相关的住院率和死亡率。除了个人保护外，广泛接种疫苗还有助于形成群体免疫，有助于减少病毒传播，促进社会正常运作的恢復。

人们对儿童疫苗接种的兴趣增加将如何促进 COVID-19 疫苗的采用？

全球疫苗接种率的上升推动了新冠疫苗市场的发展，世界各国政府都在实施全面的疫苗接种计画。根据世界卫生组织统计，截至2023年12月，全球已接种新冠疫苗135亿剂，市场渗透率庞大。新变种的出现持续推动对更新剂型的需求，同时，卫生组织也强调了对弱势族群进行加强接种的重要性。

疫苗平台的技术进步，尤其是mRNA技术的进步，改变了市场格局。美国疾病管制与预防中心报告称，在2020-2021年的早期试验中，mRNA疫苗在预防重症新冠肺炎病例方面显示超过90%的有效率。 2023年9月，辉瑞和Moderna推出了针对较新的Omicron变体的升级版单价XBB.1.5疫苗，扩大了其市场份额。

儿童疫苗和针对免疫力缺乏患者的特殊製剂日益受到关注，这正在创造新的市场机会。根据欧洲药品管理局 (EMA) 的数据，到 2023 年中期，欧盟/欧洲经济区约 82% 的 12-17 岁儿童将接种至少一剂新冠疫苗。近期，诺瓦瓦克斯 (Novavax) 宣布其新冠-流感联合疫苗将于 2024 年 3 月成功进行临床试验，这可能会彻底改变季节性疫苗接种方式，并扩大市场潜力。

哪些供应链中断阻碍了 COVID-19 疫苗市场的成长？

新冠疫苗市场面临诸多限制因素，可能影响其成长和可及性。其中一个主要限制因素是疫苗犹豫，即个人由于错误讯息、对副作用的担忧以及对製药公司的不信任而不愿或拒绝接种疫苗。这种犹豫导致疫苗接种率下降，损害了公共卫生工作，并延长了疫情。

供应链中断也为新冠疫苗市场带来了重大挑战。疫苗的快速研发和推广给生产和分销网络带来了巨大压力。原材料短缺、运输问题和物流挑战等因素可能会导致疫苗供应延迟，尤其是在中低收入国家。

监管障碍也给疫苗开发商带来了挑战，因为他们必须应对每个国家复杂的核准流程。监管标准的差异可能会减缓新疫苗的推出，并限制市场扩张。此外，还需要持续进行监测和上市后研究，以监测疫苗的安全性和有效性，这进一步增加了核准流程的复杂性。

Growing public understanding of vaccine benefits, leading to higher demand for COVID-19 vaccinations. Increased funding and support from governments and organizations to promote vaccination efforts worldwide is driving the market size surpass USD 7.64 Billion valued in 2024 to reach a valuation of around USD 12.64 Billion by 2032.

In addition to this, innovations in vaccine development and delivery methods enhancing production efficiency and distribution is spurring up the adoption of Covid-19 vaccine. Partnerships between pharmaceutical companies, governments, and NGOs accelerating research and distribution efforts is enabling the market to grow at a CAGR of 7.16% from 2026 to 2032.

Covid-19 Vaccine Market: Definition/ Overview

A COVID-19 vaccine is a biological preparation designed to provide immunity against the SARS-CoV-2 virus, which causes COVID-19. These vaccines work by introducing a harmless component of the virus, such as a spike protein or mRNA, into the body. This triggers the immune system to recognize and respond to the virus if exposed in the future, helping to prevent severe illness and transmission.

The application of COVID-19 vaccines has been crucial in controlling the pandemic. Vaccination campaigns have aimed to achieve widespread immunity in populations, significantly reducing hospitalization rates and deaths associated with the virus. In addition to individual protection, widespread vaccination contributes to herd immunity, helping to limit the virus's spread and facilitating the return to normal societal functions.

How will Growing Focus on Pediatric Vaccinations Increase Adoption of Covid-19 Vaccine?

Rising global vaccination rates have propelled the Covid-19 vaccine market forward, with governments worldwide implementing comprehensive immunization programs. According to the WHO, as of December 2023, over 13.5 billion Covid-19 vaccine doses had been administered globally, demonstrating massive market penetration. The emergence of new variants continues to drive demand for updated formulations, while health organizations emphasize the importance of booster doses for vulnerable populations.

Technological advancements in vaccine platforms have revolutionized the market landscape, particularly through mRNA technology. The US CDC reported that mRNA vaccines showed over 90% efficacy in preventing severe Covid-19 cases during initial trials in 2020-2021. In September 2023, Pfizer and Moderna launched their updated monovalent XBB.1.5 vaccines, targeting newer Omicron subvariants and expanding their market presence.

Growing focus on pediatric vaccinations and specialized formulations for immunocompromised individuals has created new market opportunities. The European Medicines Agency (EMA) data showed that approximately 82% of children aged 12-17 in the EU/EEA received at least one Covid-19 vaccine dose by mid-2023. Recently, Novavax announced successful trials of its combination Covid-19-influenza vaccine in March 2024, potentially revolutionizing the seasonal vaccination approach and expanding market possibilities.

How Supply Chain Disruptions Hampering Covid-19 Vaccine Market Growth?

The COVID-19 vaccine market faces several restraints that can impact its growth and accessibility. One major constraint is vaccine hesitancy, where individuals may be reluctant or refuse to receive the vaccine due to misinformation, fear of side effects, or distrust in pharmaceutical companies. This hesitancy can lead to lower vaccination rates, undermining public health efforts and prolonging the pandemic.

Supply chain disruptions have also posed significant challenges to the COVID-19 vaccine market. The rapid development and deployment of vaccines put immense pressure on manufacturing and distribution networks. Factors such as shortages of raw materials, transportation issues, and logistical challenges can lead to delays in vaccine availability, particularly in low- and middle-income countries.

Regulatory hurdles represent another restraint, as vaccine developers must navigate complex approval processes in various countries. Differences in regulatory standards can slow down the introduction of new vaccines and limit market expansion. Additionally, ongoing surveillance and post-marketing studies are necessary to monitor vaccine safety and efficacy, which can further complicate the approval process.

Category-Wise Acumens

Will Rise in Adoption of mRNA Technology Drive Covid-19 Vaccine Market Growth?

mRNA technology is expected to dominate Covid-19 vaccine market. The revolutionary mRNA technology is emerging as a game-changer in the Covid-19 vaccine landscape, offering unprecedented speed in vaccine development and manufacturing. According to the US FDA, mRNA vaccines demonstrated remarkable efficacy rates of 94-95% in preventing symptomatic Covid-19 infections during initial clinical trials in 2020. Moderna and Pfizer-BioNTech's success with mRNA platforms has sparked increased investment in this technology, with both companies announcing expanded research facilities and enhanced production capabilities throughout 2023 to meet global demand.

The adaptability of mRNA technology has proven crucial in responding to emerging variants, enabling rapid modification of vaccine formulations. The European Medicines Agency reported that over 600 million mRNA vaccine doses were administered in the EU/EEA by December 2023, establishing them as the predominant vaccine type. In February 2024, Moderna announced positive results from its next-generation mRNA platform trials, promising enhanced stability at regular refrigeration temperatures and potentially eliminating the ultra-cold storage requirement that initially challenged distribution.

Will Rise in Adoption of Booster Dose Drive Covid-19 Vaccine Market Growth?

Booster dose is anticipated to hold major share in the Covid-19 vaccine market. The increasing emphasis on booster doses has become a significant driver in the Covid-19 vaccine market, as health authorities worldwide recommend additional shots to maintain immunity levels. The US CDC reported that by January 2024, over 56.5% of eligible adults had received at least one booster dose, highlighting substantial market potential. Major manufacturers like Pfizer-BioNTech and Moderna have adapted their production strategies to meet this sustained demand, with both companies releasing variant-specific boosters targeting the latest strains.

Growing evidence supporting the effectiveness of booster doses in preventing severe illness has strengthened their market position. According to the UK Health Security Agency, booster shots provided 88% additional protection against hospitalization from the Omicron variant in studies conducted through 2023. In March 2024, Moderna announced positive trial results for its combination respiratory booster vaccine, which targets both Covid-19 variants and influenza strains, potentially revolutionizing the seasonal vaccination approach.

Country/Region-wise Acumens

Will Advanced Cold Chain Logistics in North America Drive Covid-19 Vaccine Market Growth?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Will Robust Healthcare Infrastructure Enhance Adoption of Covid-19 Vaccine in Asia Pacific?

Competitive Landscape

The Covid-19 vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Covid-19 vaccine market include:

Pfizer-BioNTech
Moderna
AstraZeneca
Johnson & Johnson (Janssen)
Novavax
Sinovac Biotech
Sinopharm
Sputnik V (Gamaleya Research Institute)
Bharat Biotech
COVAXIN (Bharat Biotech)
CanSino Biologics
Zydus Cadila
Valneva
Merck & Co.
Sanofi
GSK (GlaxoSmithKline)
CureVac
Vaxart
ModernaTX
Inovio Pharmaceuticals

Latest Developments

In October 2023, several pharmaceutical companies announced the results of clinical trials for new Covid-19 vaccines aimed at emerging variants, demonstrating increased efficacy and safety profiles.
In September 2023, the WHO approved a new vaccine platform designed for rapid development and deployment in response to future Covid-19 variants, enhancing global readiness.

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Covid-19 Vaccine Market, By Technology

mRNA vaccines
Viral Vector Vaccines
DNA vaccines
Protein Subunit Vaccines
Inactivated Vaccines

5. Covid-19 Vaccine Market, By Application

Primary Vaccination
Booster doses: Given

7. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

8. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

9. Competitive Landscape

Key Players
Market Share Analysis

10. Company Profiles

Pfizer
Moderna
AstraZeneca
Johnson & Johnson
Sinopharm
Sinovac Biotech
Bharat Biotech

11. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

12. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

2026-2032 年 COVID-19 疫苗市场（按技术、应用和地区）

Covid-19 Vaccine Market By Technology (mRNA Technology, Viral Vector Technology), Application (Primary Vaccination, Booster Doses), & Region for 2026-2032

COVID-19疫苗市场评估-2026-2032

人们对儿童疫苗接种的兴趣增加将如何促进 COVID-19 疫苗的采用？

哪些供应链中断阻碍了 COVID-19 疫苗市场的成长？

目录

第一章 引言

第二章执行摘要

第三章市场概述

4. COVID-19 疫苗市场（依技术）

5. COVID-19 疫苗市场（按应用）

第七章区域分析

第八章市场动态

第九章 竞争态势

第十章 公司简介

第十一章 市场展望与机会

第十二章 附录

Covid-19 Vaccine Market Valuation - 2026-2032